Objective To systematically review the clinical research progress, current status and prospects of “interventional dual conversion therapy”. MethodsWe systematically sorted out and summarized interventional dual conversion therapy by retrieving domestic and foreign basic and clinical studies on oncological conversion and functional conversion therapy for liver cancer in the past 10 years. ResultsInterventional dual conversion therapy comprises oncological conversion [including transarterial chemoembolization (TACE), hepatic artery infusionchemotherapy, selective internal radiation therapy, and systemic therapy] and functional conversion [including portal vein embolization (PVE), liver venous deprivation, liver function improvement and antiviral therapy]. This strategy improves the conversion resection rate, reduces the risk of losing radical resection opportunity due to primary tumor progression, and prolongs long-term survival. Preliminary clinical studies have confirmed the efficacy of its synergistic strategy: drug-eluting beads transarterial chemoembolization combined with PVE, TACE combined with PVE (superior to PVE alone), 90Y sequential PVE, drug-eluting beads transarterial chemoembolization+PVE+targeted therapy+immunotherapy therapy and AITI model combined with ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) all achieved good conversion resection effects. Currently, relevant clinical studies are still in the preliminary exploration stage, and prospective large-scale studies are urgently needed. ConclusionInterventional dual conversion therapy can improve the resection rate and long-term prognosis of advanced liver cancer patients through minimally invasive methods, and establish a new paradigm for liver cancer conversion management.
